Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06886113

CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial

Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%. An alternative to current management is restoration of the volume of blood pumped by the heart (cardiac output) using a ventricular assist device. In the acute setting this is difficult but can be done using the CorVad device which is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation thereby restoring blood flow to the failing organs. The hypothesis of the current study is to reduce mortality and morbidity of patients with cardiogenic shock using the CorVad device. The study will be carried out as a randomized multicenter study where eligible patients will be randomized to receive conventional circulatory support or support with the CorVad device and inotropic support if needed. A total of 269 patients are planned

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China

Location contact

About this study

The study is a prospective, multicenter trial in patients with AMICS randomized 1:1 to CorVad or current guideline-driven therapy with planned enrollment of 269 patients. Patients comatose after out of hospital cardiac arrest are excluded. Eligible patients are randomized immediately following shock diagnosis. Among patients randomized to receive CorVad, the device is placed prior to angioplasty. The primary endpoint is all-cause mortality at 180 days.The target population of subjects are patients with acute myocardial infarction with cardiogenic shock who need high-risk PCI treatment, and sign an informed consent form (ICF) approved by the Ethics Committee (EC). Subjects who meet the enrolment criteria as judged by the investigator will apply the trial product according to the requirements and will be followed up to 180 days after the procedure.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ST segment elevation myocardial infarction of less than 36 hours' duration, confirmed by new onset ST-segment elevation, or emergency angiography demonstrating acute occlusion of coronary artery, and
  • Cardiogenic shock of less than 24 hours' duration, confirmed by:

peripheral signs of tissue hypoperfusion (arterial blood lactate ≥2.5mmol/l and/or SvO2 <55% with a normal PaO2) and systolic blood pressure less than 100mmHg and/or need for vasopressor therapy (dopamine/ norepinephrine or epinephrine), and

  • Left ventricular ejection fraction of less than 45% visually estimated or by wall motion score index >1,6.

Exclusion criteria

  • Shock duration N24 hours
  • Other causes of shock; hypovolemia, sepsis, pulmonary embolism or anaphylaxis
  • Shock due to mechanical complication to myocardial infarction; papillary muscle rupture, rupture of the ventricular septum or rupture of ventricular free wall.
  • Severe aorta valve regurgitation/stenosis
  • Severe peripheral arterial obstructive disease that would preclude Impella device placement
  • Mechanical aortic valve prosthesis
  • Already established mechanical circulatory support (Impella or VA-ECMO)
  • Left ventricular thrombus
  • Infective endocarditis
  • Shock due to right ventricular failure
  • Out of hospital cardiac arrest with persistent Glasgow coma scale b8 after return of spontaneous circulation. Cardiac arrest occurring in ambulance or after arrival to hospital is not an exclusion criterion.
  • Subject with documented heparin induced thrombocytopenia.
  • Life expectancy of less than 1 year due to comorbidities.
  • Mental disorder or language barrier that preclude informed

Treatment and study plan

Conventional circulatory support

Device

Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs

CorVad

Device

Control group treated with Impella CP for a minimum of 48 hrs

Primary outcomes

  1. Death

    Time frame: up to 6 months

    Death from all causes

Secondary outcomes

  1. MACCE

    Time frame: minimum follow-up 6 months

    Major cardiovascular and cerebrovascular events, death, cardiac transplant, escalation to permanent left ventricular assist device, re-hospitalization for heart failure

  2. Composite saftey

    Time frame: up to 6 months

    Rate of major bleeding, vascular complications, and significant hemolysis

  3. Days alive out of hospital

    Time frame: up to 6 months

    Days alive and out of hospital, calculated by subtracting the number of days spent in hospital, from time of randomization to end of follow-up (180 days) for each patient

Other outcomes

  1. Hemodynamics

    Time frame: up to 7 days

    Cardiac power index

  2. Hemodynamics

    Time frame: up to 7 days

    Lactate clearence

  3. Hemodynamics

    Time frame: up to 7 days

    Pulmonary artery pulsatility index

  4. Renal function

    Time frame: up to 30 days

    Number of Participants with acute kidney injury or need for dialysis

  5. Bleeding

    Time frame: up to 30 days

    Rate of bleeding complications during admission

  6. Revascularization strategy

    Time frame: During procedure

    Syntax score ( a grading system that evaluates the complexity and prognosis of patients undergoing percutaneous coronary intervention, higher scores denotes more complex disase and higher risk)

Study contacts

Contact information is provided by the study sponsor or research team.

Xiaoli Shi VP

CONTACT

[email protected]

+86 13418601356

Sponsors and collaborators

Lead sponsor

Shenzhen Core Medical Technology CO.,LTD.

Industry

Registry information

Official study title

Effects of CorVad Percutaneous Mechanical Circulatory Support in Patients with ST Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock.

Acronym: Corvad AMICS

Important dates

Study start
2025
Primary completion
2026
Study completion
2028
First posted
Mar 20, 2025
Registry last updated
Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.